| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Carboxylesterase 5A, Carboxylesterase-like urinary excreted protein homolog, Cauxin, CES5A, CES7 |
| Entrez GeneID | 221223 |
| WB Predicted band size | 63.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CES7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 244-270 amino acids from the Central region of human CES7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CES7抗体的参考文献示例(注：以下内容为虚构示例，建议通过学术数据库查询真实文献)：
---
1. **"Characterization of a Novel Monoclonal Antibody for Human Carboxylesterase 7 (CES7) in Digestive Tissues"**
*Authors: Zhang Y, Li H, Wang J*
摘要：本研究开发了一种特异性靶向人CES7的单克隆抗体，验证了其在Western blot和免疫组化中的适用性，发现CES7在肠道和肝脏中高表达，提示其在脂质代谢中的潜在作用。
2. **"CES7 Expression in Colorectal Cancer: Prognostic Implications and Antibody Validation"**
*Authors: Smith R, Patel K, Brown L*
摘要：通过免疫组化分析结直肠癌组织，利用抗CES7抗体发现其表达水平与患者生存率负相关，表明CES7可能作为癌症预后的生物标志物。
3. **"Role of CES7 in Drug Metabolism: Insights from Knockout Mouse Models"**
*Authors: Johnson M, Tanaka S, Lee C*
摘要：使用特异性CES7抗体检测基因敲除小鼠模型，证实CES7参与特定前药(如抗病毒药物)的代谢活化，为个体化用药提供依据。
4. **"Development of a High-Specificity Polyclonal Antibody for CES7 in Neurodegenerative Disease Studies"**
*Authors: García A, Müller P, Kim D*
摘要：报道一种高特异性CES7多克隆抗体的开发，并用于阿尔茨海默病模型脑组织分析，发现CES7表达与淀粉样蛋白沉积相关。
---
建议通过PubMed、Web of Science等平台搜索关键词“CES7 antibody”或“carboxylesterase 7”获取真实文献。
CES7 antibody is a research tool targeting carboxylesterase 7 (CES7), a member of the carboxylesterase enzyme family involved in xenobiotic metabolism and lipid processing. CES enzymes hydrolyze ester- or amide-containing compounds, including drugs, environmental toxins, and endogenous substrates. While CES1 and CES2 are well-characterized isoforms, CES7 (also termed CES7A1 or hCE3) is less studied but shares conserved catalytic domains. It is expressed in tissues like the liver, intestines, and macrophages, suggesting roles in drug detoxification, lipid regulation, and inflammatory responses.
CES7 antibodies are primarily used to detect and quantify CES7 protein expression in experimental models, aiding studies on its physiological functions and disease associations. Research indicates CES7 may influence drug efficacy/toxicity (e.g., prodrug activation) and metabolic disorders such as atherosclerosis due to its interaction with cholesterol esters. Antibodies against CES7 enable immunohistochemical localization, Western blot analysis, and inhibition assays, helping clarify its tissue-specific activity and regulatory mechanisms. Emerging interest in CES7 also stems from its potential as a biomarker or therapeutic target in cancer and metabolic diseases. However, functional overlap with other CES isoforms and incomplete characterization of CES7-specific pathways remain challenges. Current antibody development focuses on improving specificity to distinguish CES7 from homologous enzymes, enhancing reliability in both basic research and clinical applications.
×
